BioNTech counts on shift to cancer drugs after second quarter losses quadruple
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
BioNTech (BNTX) PT Lowered to $93 at Morgan Stanley
August 5, 2024 2:32 PM EDTMorgan Stanley analyst Terence Flynn lowered the price target on BioNTech (NASDAQ: BNTX) to $93.00 (from $101.00) while maintaining a Equalweight rating.
The analyst comments "BNTX reported a beat on revs but a miss on the bottom line due to higher OpEx. 2024 guidance was reiterated. Upcoming... More
